SARRP with Cone Beam CT and bioluminescence imaging guidance

项目名称：采用锥形束CT和生物发光成像引导的SARRP 项目总结/摘要 拟议收购Xstrahl生命科学200小动物辐射仪， 辐射研究平台（SARRP），将提供三维生物发光光学成像的新能力， 肯塔基州大学，以满足16个NIH资助的研究人员的需要，他们的研究项目有一个 迫切需要能够从多个角度提供高度适形辐射的仪器， 具有图像引导的临床前小动物模型，用于模拟临床放射治疗的剂量分布。 来自Xstrahl的SARRP系统能够从多个非放射性物质中为小动物提供精确的照射。 共面角此外，集成计算机断层扫描（CT）以及生物发光等功能 断层扫描（BLT）提供有关肿瘤的精确几何和生物信息， 科学家们更好地模拟临床使用的放射治疗，以及监测 非侵入性放射治疗。该仪器在临床前放射治疗中提供高精度， 这使得对肿瘤的剂量更高，对有风险的器官的剂量更低， 控制，毒性更低，并有可能将先进的新的高精度发现转化为更高的整体 临床实践中的生存。该仪器平台将被安置在一个共享使用的设施在大学 肯塔基州的毒理学和癌症生物学系解决了癌症生物学的强烈需求 研究人员模仿临床放射治疗，并将支持23个积极的赠款（21个由美国国立卫生研究院资助）， 所有这些都涉及到辐射的使用。重要的是，SARRP提供的新仪器功能将 更换两个老化的放射性同位素（铯）辐照器，这两个辐照器处于使用寿命结束阶段， 构成安全风险。这些系统缺乏用于靶向辐射递送的有效手段。因此，新 仪器将提供上级精确的光束瞄准，以显着增强研究结果。的 该大学还拥有一个kV X射线盒装系统，用于辐射研究。然而，这个系统完全 不足以用于现代研究发现，因为它缺乏提供倾斜光束的能力， 因此主要用于细胞辐射。这台Xstrahl仪器的加入将大大提高 肯塔基州大学国家癌症研究所指定的癌症生物学研究 该中心拥有大量在癌症生物学和辐射方面具有专业知识的成员 research.拥有19个R 01或同等赠款的13个主要用户和3个次要用户将组成初始用户 SARRP的基地。还将制定详细的推广计划，以吸引更多的研究人员使用这一 仪器肯塔基州大学作出了重大的机构承诺，以确保成功的 设备安装后的使用，从而确保高端癌症研究的操作连续性， 小动物辐射的最新技术。

Project title: SARRP with Cone Beam CT and bioluminescence imaging guidance Project Summary/Abstract The proposed acquisition of the Xstrahl Life Sciences 200 Small Animal Radiation Instrument, a small animal radiation research platform (SARRP), will provide new capabilities for 3D bioluminescent optical imaging at the University of Kentucky to meet the needs of 16 NIH-funded investigators whose research programs have a critical need for instrumentation that is capable of delivering highly conformal radiation from multiple angles to preclinical small animal models with image guidance for a dose distribution mimicking clinical radiotherapy. The SARRP system from Xstrahl is able to provide precise irradiation to a small animal from multiple non- coplanar angles. In addition, features such as integrated computed tomography (CT) as well as bioluminescent tomography (BLT) provide precise geometric and biological information about the tumor, allowing basic scientists to better model delivery of radiation therapy that is used clinically, as well as to monitor the effects of radiation therapy non-invasively. The instrument offers high precision in preclinical radiation therapy treatment, which enables a higher dose to the tumor with lower dose to organs at risk with demonstrated high local control, less toxicity and the potential to translate advanced new high-precision findings to increased overall survival in clinical practice. This instrument platform to be housed in a shared use facility in the University of Kentucky’s Department of Toxicology and Cancer Biology addresses a strong need for cancer biology researchers to mimic clinical radiotherapy treatment and will support 23 active grants (21 funded by the NIH), all of which involve the use of radiation. Importantly, the new instrument capabilities offered by the SARRP will replace two aging radio-isotopic (Cesium) based irradiators that are at the end of their useful life stage and that pose a security risk. These systems lack an effective means for targeted radiation delivery. Thus, the new instrument will provide superior precision beam targeting for significantly enhanced research results. The university also has a kV x-ray boxed system for radiation research. However, this system is completely inadequate for modern research discovery, as it lacks the capability to deliver an angled beam and has therefore been used primarily for cell irradiation. The addition of this Xstrahl instrument will greatly enhance cancer biology research within the University of Kentucky’s National Cancer Institute-designated Cancer Center, which encompasses large numbers of members with expertise in cancer biology and radiation research. Thirteen major users with 19 R01 or equivalent grants and three minor users will form the initial user base for the SARRP. Detailed outreach plans will also be established to attract more researchers to use this instrument. University of Kentucky has made a significant institutional commitment to ensure the successful use of the device after its installation, thereby ensuring operational continuity of high-end cancer research and the latest technology in small animal irradiation.